🔗 Share this article

Given that the United States undertakes sweeping changes to its vaccination recommendations, one figure has surfaced in a surprising turn: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the global health crisis and has zeroed in on possible fatalities after Covid immunization in her short position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Public health authorities had intended to announce radical revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of step with a large portion of the international standard with insufficient data for public health gain. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is set to address the audience at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this year.

A Shift at the Agency

This interim role might represent a strengthened alliance between the drug and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric shot schedules in the US so as to align more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants approximately the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Høeg has no apparent background in drug development, oversight or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a large organization. She lacks background in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that former directors who headed CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock pointed out.

“Many people just focuses on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and all of those have to be managed,” Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a major management component to the role, which manages in excess of 5,000 employees. “It is a massive management job, if you execute it properly,” the former official added.

Agency Reaction and Disputed Policies

In response to questions about Dr. Høeg's credentials and whether this selection represents greater collaboration among agency officials on immunizations, a spokesperson stated that the “questions are based on incorrect assumptions”.

“Her experience matches the responsibilities of her role,” the representative stated, citing the period Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious rapid therapy clearance system that reportedly worried her former heads. “How are these medications being picked for this voucher program? Who makes the decisions?” Dr. Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Public History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, history, Howard observe. She released a study using non-validated volunteer-provided data to assess the rate of heart inflammation after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are more dangerous than they are.

Part of her “wish list” for the incoming administration included altering rules for new vaccines and discontinuing “optional” immunizations, she stated post-election on a online show. At the agency, Dr. Høeg has reportedly suggested barring young men from receiving COVID-19 vaccinations.

“She’s an thorough ideologue who starts off with her beliefs and tailors the evidence to retrofit the science in a highly disingenuous, dishonest fashion,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|